Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Captopril

Francheska Marte  1 , Parvathy Sankar  2 , Preeti Patel, Manouchkathe Cassagnol  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Book

Captopril

Francheska Marte et al.

Excerpt

Captopril is an FDA-approved medication that plays a pivotal role in managing hypertension, left ventricular dysfunction post-myocardial infarction, and diabetic nephropathy. Its therapeutic efficacy primarily stems from inhibiting the renin-angiotensin-aldosterone system (RAAS), making it a cornerstone in treating these cardiovascular conditions. Captopril effectively mitigates the pathophysiological cascades contributing to hypertension and heart failure by impeding the conversion of angiotensin I to angiotensin II. This activity sheds light on captopril's mechanism of action, dosage considerations, pharmacodynamics, and monitoring strategies. Additionally, captopril's off-label uses in acute hypertensive crises and the Raynaud phenomenon will be discussed, equipping clinicians and interprofessional team members with essential knowledge to administer captopril. Awareness of its adverse event profile and potential toxicities is crucial in ensuring captopril's safe and effective integration into clinical practice.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Francheska Marte declares no relevant financial relationships with ineligible companies.

Disclosure: Parvathy Sankar declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.

References

    1. Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170. - PMC - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 03;79(17):e263-e421. - PubMed
    1. Rout P, Jialal I. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2025. Jan 9, Diabetic Nephropathy. - PubMed
    1. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 01;45(12):3075-3090. - PMC - PubMed
    1. Karakiliç E, Büyükcam F, Kocalar G, Gedik S, Atalar E. Same effect of sublingual and oral captopril in hypertensive crisis. Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1642-5. - PubMed

Publication types